MUC1 and invasive breast carcinoma: In vitro characterization and cell viability assays ensured the efficacy of the aptamer-conjugated NPs and established PTX-S2.2 and HNK-S2.2 PBM NPs as potentially viable treatment options for MUC1-expressing BrCa.